ZA202100955B - Thrombin inhibitors, formulations, and uses thereof - Google Patents

Thrombin inhibitors, formulations, and uses thereof

Info

Publication number
ZA202100955B
ZA202100955B ZA2021/00955A ZA202100955A ZA202100955B ZA 202100955 B ZA202100955 B ZA 202100955B ZA 2021/00955 A ZA2021/00955 A ZA 2021/00955A ZA 202100955 A ZA202100955 A ZA 202100955A ZA 202100955 B ZA202100955 B ZA 202100955B
Authority
ZA
South Africa
Prior art keywords
formulations
thrombin
thrombin inhibitors
compounds
pyrazole
Prior art date
Application number
ZA2021/00955A
Other languages
English (en)
Inventor
Michael Short Kevin
De Los Angeles Estiarte-Martinez Maria
Ben Kita David
Sudath Sirisoma Nilantha
Original Assignee
Verseon Int Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseon Int Corporation filed Critical Verseon Int Corporation
Publication of ZA202100955B publication Critical patent/ZA202100955B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2021/00955A 2018-07-13 2021-02-11 Thrombin inhibitors, formulations, and uses thereof ZA202100955B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697817P 2018-07-13 2018-07-13
PCT/US2019/041699 WO2020014669A1 (en) 2018-07-13 2019-07-12 Thrombin inhibitors, formulations, and uses thereof

Publications (1)

Publication Number Publication Date
ZA202100955B true ZA202100955B (en) 2023-10-25

Family

ID=67470750

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/00955A ZA202100955B (en) 2018-07-13 2021-02-11 Thrombin inhibitors, formulations, and uses thereof

Country Status (13)

Country Link
US (1) US11865110B2 (cg-RX-API-DMAC10.html)
EP (1) EP3820564B1 (cg-RX-API-DMAC10.html)
JP (2) JP2021531338A (cg-RX-API-DMAC10.html)
KR (1) KR20210080347A (cg-RX-API-DMAC10.html)
CN (1) CN113164765B (cg-RX-API-DMAC10.html)
AU (1) AU2019300161B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021000515A2 (cg-RX-API-DMAC10.html)
CA (1) CA3106359A1 (cg-RX-API-DMAC10.html)
IL (1) IL280078B2 (cg-RX-API-DMAC10.html)
MX (1) MX2021000472A (cg-RX-API-DMAC10.html)
SG (1) SG11202100247WA (cg-RX-API-DMAC10.html)
WO (1) WO2020014669A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202100955B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116735514B (zh) * 2023-08-11 2023-11-03 昆明理工大学 纳米酶结合液液微萃取快速检测天麻硫熏标志物的方法
WO2025184627A1 (en) * 2024-03-01 2025-09-04 Cadrenal Therapeutics, Inc. Method for preventing coagulation in patients with implanted cardiac devices

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5579843A (en) 1994-08-16 1996-12-03 Loitherstein; Joel S. Resilient spider for well installation
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SI21097A (sl) 2001-12-04 2003-06-30 Univerza V Ljubljani Inhibitorji trombina
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
JP2009543842A (ja) 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
CA2734804A1 (en) 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
JP2012500244A (ja) 2008-08-19 2012-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍療法におけるダビガトラン
JP2012500245A (ja) 2008-08-19 2012-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 経皮的インターベンション心臓カテーテル法のためのダビガトラン
DK2968297T3 (en) * 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) * 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物

Also Published As

Publication number Publication date
JP2021531338A (ja) 2021-11-18
KR20210080347A (ko) 2021-06-30
EP3820564B1 (en) 2026-07-08
JP2025098029A (ja) 2025-07-01
CN113164765B (zh) 2026-03-20
IL280078B2 (en) 2024-04-01
US20210315877A1 (en) 2021-10-14
SG11202100247WA (en) 2021-02-25
CN113164765A (zh) 2021-07-23
EP3820564A1 (en) 2021-05-19
CA3106359A1 (en) 2020-01-16
IL280078A (en) 2021-03-01
WO2020014669A1 (en) 2020-01-16
US11865110B2 (en) 2024-01-09
BR112021000515A2 (pt) 2021-04-06
IL280078B1 (en) 2023-12-01
AU2019300161A1 (en) 2021-02-25
AU2019300161B2 (en) 2025-05-22
MX2021000472A (es) 2021-06-23

Similar Documents

Publication Publication Date Title
MY209609A (en) Immunomodulators, compositions and methods thereof
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2021004431A (es) Procesos novedosos.
MY210070A (en) Heterocyclic compounds as immunomodulators
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
PH12018501920B1 (en) Bromodomain inhibitors
PH12020552154A1 (en) Compounds
ZA202204941B (en) Cd73 inhibitors
EP4464317A3 (en) Compounds and compositions and uses thereof
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MY174747A (en) Bace1 inhibitors
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2020007974A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2021013602A (es) Inhibidores de jak.
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
PH12021550258A1 (en) Cdk8/19 inhibitors
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2021000472A (es) Inhibidores de trombina, formulaciones y usos de estos.
PH12021550093A1 (en) Compounds for use in the treatment of fascioliasis
PH12017501668A1 (en) Bace1 inhibitors
MX2022016272A (es) Derivados de tetrazol como inhibidores de trpa1.